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OBJECTIVE—To examine ankle-brachial index (ABI) abnormalities in patients with type 2
diabetes and coronary artery disease (CAD).
RESEARCH DESIGN AND METHODS—An ABI was obtained in 2,240 patients in the
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. ABIs were clas-
siﬁed as: normal, 0.91–1.3; low, #0.9; high, .1.3; or noncompressible artery (NC). Baseline
characteristics were examined according to ABI and by multivariate analysis.
RESULTS—ABI was normal in 66%, low in 19%, and high in 8% of patients, and 6% of
patientshadNC.OfthelowABIpatients,68%wereasymptomatic.UsingnormalABIasreferent,
low ABI was independently associated with smoking, female sex, black race, hypertension, age,
C-reactive protein, diabetes duration, and lower BMI. High ABI was associated with male
sex,nonblackrace,and higherBMI;and NCartery wasassociatedwith diabetesduration,higher
BMI, and hypertension.
CONCLUSIONS—ABI abnormalities are common and often asymptomatic in patients with
type 2 diabetes and CAD.
Diabetes Care 34:464–467, 2011
T
hereislimiteddataonankle-brachial
index(ABI)abnormalitiesinpatients
with type 2 diabetes and coronary
artery disease (CAD). Using the Bypass
Angioplasty Revascularization Investiga-
tion 2 Diabetes (BARI 2D) Trial, our aim
was to compare the prevalence and risk
factors associated with normal, low, and
high ABI and noncompressible artery
(NC). We hypothesized that due to the
different pathogenesis of obstructive pe-
ripheral artery disease (PAD) and arterial
stiffness, the risk factors for these condi-
tions would differ.
RESEARCH DESIGN AND
METHODS—Details of the BARI 2D
Trial have been previously published
(1,2). The local institutional review
boards approved the protocols, and par-
ticipants provided informed consent.
The study population included 2,240 pa-
tients that had an ABI assessment at base-
line.
ABI protocol
Central training was provided, and a
standard protocol for obtaining ABIs
was used. Patients were placed supine
for at least 5 min. The systolic blood
pressure of the brachial artery of both
armsandtheposteriortibialarteryofboth
ankles were measured using a blood
pressure cuff and a Parks Model 841-A
pocket Doppler probe (Parks Medical
Electronics, Aloha, OR). The highest
arm pressure was used to calculate ABI.
The ratio of ankle to arm systolic blood
pressure was calculated for each leg, and
the lowest ratio was recorded as the ABI.
ABIs were classiﬁed as: low #0.9, normal
0.91–1.3, and high .1.3or NC when the
operator was unable to occlude the ankle
artery with maximum cuff inﬂation.
Asymptomatic PAD was deﬁned as a low
ABI in the absence of physician-reported
claudication.
Statistical analysis
We compared clinical characteristics be-
tween ABI groups using the normal ABI
group as referent. We used x
2 tests for
categorical variables and Student t tests
for continuous variables. Associations be-
tween clinical variables and presence of
low ABI, high ABI, or NC artery were as-
sessed with logistic regression using pre-
dictor variables that had biological
plausibility for being causally related to
t h eo u t c o m ev a r i a b l e .W ep r e s e n to d d s
ratios (ORs) (95% CIs) for this model. A
value of P # 0.05 was considered statisti-
cally signiﬁcant. SAS version 9 for Win-
dows was used for all analyses (version
9.2; SAS Institute).
RESULTS
Baseline characteristics according
to ABI
The distribution of ABI was approxi-
mately symmetrical, with a mean value
of 1.05. A normal ABI was found in 66%
(n = 1,489), low ABI in 19% (n = 430),
high ABI in 8% (n = 182), and NC artery
in 6% (n = 139) of patients. The baseline
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Singh and Associatescharacteristics according to ABI are pre-
sented (Table 1).
ABI and lower extremity symptoms
With respect to symptoms status, 68% of
patients with a low ABI did not have
claudication. Compared with low-ABI
patients with claudication, aymptomatic
subjects had higher mean ABI values
(0.75 vs. 0.66, P , 0.0001), were less
likely to have peripheral neuropathy
(28 vs. 55%, P , 0.0001), carotid artery
disease (8 vs. 29%, P , 0.0001), and
chronic renal dysfunction (3 vs. 8%, P =
0.047), and were less likely to be current
smokers (16 vs. 31%, P = 0.0003), sug-
gesting that the severity of atherosclerotic
disease may play a role.
Abnormal ABI risk factors
After adjustment, with normal ABI as
referent, low ABI was independently as-
sociated with older age, female sex, black
race, diabetes duration, lower mean BMI,
hypertension,currentsmoking,andhigher
C-reactive protein (CRP). Using similar
methodology, a high ABI was associated
with male sex, nonblack race, nonsmok-
i n gs t a t u s ,a n dh i g h e rm e a nB M I ;a nN C
artery was associated with diabetes dura-
tion,highermeanBMI,andhypertension
(Table 1).
CONCLUSIONS—In this large study
of patients with type 2 diabetes and CAD,
wefound ahigh prevalence of obstructive
PAD and arterial stiffness and identiﬁed
risk factors for an abnormal ABI. A longer
duration of type 2 diabetes and hyper-
tension were independently associated
with a low ABI and NC artery. Certain
factors, however, were associated only with
a low ABI, such as older age, female sex,
black race, current smoking, and higher
CRP level. A higher prevalence of PAD
among women and blacks has been ob-
served and does not appear to be due to
known atherosclerosis risk factors (3,4).
Our study extends these ﬁndings to pa-
tients with type 2 diabetes and CAD. The
higher prevalence of PAD in women and
blacks may be due to biologic or social
differences, as well as slightly lower nor-
mal ABI values in these populations (5).
Older age, smoking, and CRP, similar to
ourstudy,areassociatedwiththepresence
or progression of PAD in patients with di-
abetes (6,7).
SimilartoalowABI,ahighABIorNC
artery is associated with an increased risk
of mortality, cardiovascular events, and
amputation (8–10). We observed a high
prevalence of arterial stiffness, similar to
that seen in older individuals, American
Indians, and dialysis patients (9,10). As
observed in our study, diabetes duration
has been identiﬁed as a risk factor for
obstructive PAD and arterial stiffness
(11,12). Unlike PAD outcomes, which
are not known to improve with glycemic
control, intensive treatment of diabetes
can reduce peripheral arterial calciﬁcation
and therefore may prevent development
of NC arteries (13). The association be-
tween higher mean BMI and a high ABI
or NC artery in our population may be
related directly to adiposity or differences
in physical activity levels.
This is a large study of well-
characterizedpatientsthatincludesalarge
number of women and minority ethnic
groups. Limitations include the cross-
sectional study design, which limits any
conclusions about causality, the fact that
ABI measurement may not detect all ob-
structive PAD, and the fact that an NC
artery can mask obstructive PAD.
I ns u m m a r y ,w eh a v es h o w nt h a t
both an abnormally low or high ABI are
commoninpatients with establishedtype
2 diabetes and CAD and that associated
factors can be identiﬁed and deserve
further study of causality. Prior studies
have shown that PAD is frequently over-
looked in high-risk patients and that the
absence of symptoms does not modify
the risk of cardiovascular events (14). The
high prevalence of asymptomatic patients
in our study supports the recommenda-
tions for a more aggressive approach to
PAD detection. Whether early identiﬁ-
cation of PAD and implementation of
aggressive medical measures can inﬂu-
ence the progression of lower-extremity
vascular disease or associated cardiovas-
cular mortality in type 2 diabetes is
unknown.
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